Oral Controlled Release Drug Delivery Technology Market Demand, Supply, Growth Factors, Latest Rising Trend and Forecast to 2027

Future Market Insights (FMI), in its report, projects the global oral controlled release drug delivery technology market to register an impressive expansion at 7.2% CAGR during the forecast period 2017 to 2027. The market will surpass revenues worth US$ 20,000 Mn in 2017, and is further estimated to reach nearly US$ 50,000 Mn by 2027-end.

Oral Solid Dosage Manufacturers in North America Enabled to Achieve Significant Bioavailability

FMI’s report estimates North America to remain the largest market for oral controlled release drug delivery technology, with sales estimated to reach nearly US$ 20,000 Mn by 2027-end. Being preferred route of drug administration by physicians, demand for oral controlled release drug delivery technology has been witnessing a surge by end-users in North America. In addition, recent advancements in drug delivery have enabled oral solid dosage manufacturers in North America to achieve significant bioavailability through adoption of novel drug delivery platforms. This is further expected to drive demand for oral controlled release drug delivery technology in the region.

To Get Sample Copy of Report visit @ https://www.futuremarketinsights.com/reports/sample/REP-GB-4400

However, increasing research activities related to biologic molecules, and their dominance in treating oncology conditions, coupled with government investments in these research activities are expected to impede the market growth in North America. In addition, formulation challenges such as juncture of market expectations for once-daily dosing, and growth of controlled release tablets which impart abuse resistance, incurred in oral controlled release drug delivery technology are expected to further curb growth of the market in this region.

New Chemical Entities Resulting from High Throughput Screening to Drive Market Growth in Western Europe

Western Europe will register the fastest expansion in the global oral controlled release drug delivery technology market. This growth is primarily attributed to a slew of new chemical entities resulting from high throughput screening, which have low solubility and bioavailability. This has further led manufacturers in this region to invest in drug delivery methods with better clinical outcome. Owing to cost-sensitiveness in Western European countries, technologies enhancing bioavailability will remain preferred drug delivery system. These factors are expected to drive growth of the market in this region.

Oral Controlled Release Drug Delivery Technology Market

However, most of the pharmaceutical companies in Western Europe have complex supply chain, which is either under-utilised or inefficient. Complexity of supply chain is attributed to low flexibility and cost-effectiveness. In addition, shortening of effective patent life along with patent cliffs is a major challenge for oral solid dosage forms in this region. Factors such as these are estimated to hinder growth of the market in Western Europe.

Dissolution-Controlled Release System to Remain Sought-After among Drug Release Technologies in the Market

By drug release technology, dissolution-controlled release system will remain sought-after in the market, followed by diffusion-controlled release system. Majority of generic formulations available are in tablet dosage form and follow dissolution-controlled release mechanism. Revenues from sales of dissolution-controlled release system will surpass US$ 10,000 Mn in 2017. Demand for hydrodynamically-balanced drug delivery system will remain sluggish in the market.

Solid dosage forms of oral controlled release drug delivery technology are expected to remain dominant in the market, expanding at a high single-digit CAGR through 2027. Sales of semisolid/liquid/suspensions dosage form segment will register a comparatively lower CAGR than that of solid dosage forms in the market through 2027.

Key market players identified in FMI’s report include AstraZeneca Plc., Bristol-Myers Squibb Company, Sun Pharmaceuticals Industries Ltd, Abbott Laboratories, Merck & Co. Inc.,Novartis AG, Pfizer Inc., Mylan N.V., Sanofi, F. Hoffman-La-Roche Ltd., Johnson & Johnson Services, Inc., Vectura Group plc., GlaxoSmithKline plc.

Ask an Analyst @ https://www.futuremarketinsights.com/ask-question/rep-gb-4400

Why Future Market Insights?
· Comprehensive analysis on evolving purchase pattern across different geographies
· Detailed insights of market segments and sub-segments for historical as well as forecast period
· A competitive analysis of prominent players and emerging players in the keyword market
· Detailed information about the product innovation, mergers and acquisitions lined up in upcoming years
Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario

About FMI:
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact Us:
Mr. Debashish Roy
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
MARKET ACCESS DMCC Initiative
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com